Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Harrow Health Stock Up 11.6 %
Shares of HROW Stock traded up $0.89 on Thursday, hitting $8.54. 116,275 shares of the stock were exchanged, compared to its average volume of 86,342. The company has a current ratio of 6.79, a quick ratio of 6.31 and a debt-to-equity ratio of 7.38. The firm has a market capitalization of $230.84 million, a P/E ratio of -9.30 and a beta of 0.78. The business has a 50-day moving average of $6.99 and a 200 day moving average of $7.07. Harrow Health has a fifty-two week low of $5.40 and a fifty-two week high of $12.99.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on HROW shares. TheStreet cut Harrow Health from a "c-" rating to a "d+" rating in a research note on Thursday, May 19th. B. Riley boosted their target price on Harrow Health from $17.00 to $20.00 and gave the company a "buy" rating in a research note on Friday, May 20th.